David Haynor

Dr. David Haynor


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 October 2024 in Cancers
Verified
Journal Article
Open access
PDF file
JAJavid Azadbakht
Javid Azadbakht
ACAmy Condos
Amy Condos
DHDavid Haynor
David Haynor
WGWende N. Gibbs
Wende N. Gibbs
PMPejman Jabehdar Maralani
Pejman Jabehdar Maralani
SLSimon Lo
Simon Lo
Spine metastases (SMs) are common, arising in 70% of the cases of the most prevalent malignancies in males (prostate cancer) and females (breast cancer). Stereotactic body radiotherapy, or SBRT, has been incorporated into clinical treatment algorithms over the past decade. SBRT has shown promising rates of local control for oligometastatic spinal lesions with low radiation dose to adjacent critical tissues, particularly the spinal cord. Imaging is critically important in SBRT planning, guidance, and response monitoring. This paper reviews the roles of imaging in spine SBRT, including conventional and advanced imaging approaches for SM detection, treatment planning, and post-SBRT follow-up.

20 March 2024 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
PDF file
LSLan Shui
Lan Shui
DSDean Shibata
Dean Shibata
KCKwun Chuen Gary Chan
Kwun Chuen Gary Chan
WZWenbo Zhang
Wenbo Zhang
JSJunhyoun Sung
Junhyoun Sung
AIAlzheimer’S Disease Neuroimaging Initiative
Alzheimer’S Disease Neuroimaging Initiative
Background: Longitudinal magnetic resonance imaging (MRI) has been proposed for tracking the progression of Alzheimer’s disease (AD) through the assessment of brain atrophy. Objective: Detection of brain atrophy patterns in patients with AD as the longitudinal disease tracker. Methods: We used a refined version of orthonormal projective non-negative matrix factorization (OPNMF) to identify six distinct spatial components of voxel-wise volume loss in the brains of 83 subjects with AD from the ADNI3 cohort relative to healthy young controls from the ABIDE study. We extracted non-negative coefficients representing subject-specific quantitative measures of regional atrophy. Coefficients of brain atrophy were compared to subjects with mild cognitive impairment and controls, to investigate the cross-sectional and longitudinal associations between AD biomarkers and regional atrophy severity in different groups. We further validated our results in an independent dataset from ADNI2. Results: The six non-overlapping atrophy components represent symmetric gray matter volume loss primarily in frontal, temporal, parietal and cerebellar regions. Atrophy in these regions was highly correlated with cognition both cross-sectionally and longitudinally, with medial temporal atrophy showing the strongest correlations. Subjects with elevated CSF levels of TAU and PTAU and lower baseline CSF Aβ 42 values, demonstrated a tendency toward a more rapid increase of atrophy. Conclusions: The present study has applied a transferable method to characterize the imaging changes associated with AD through six spatially distinct atrophy components and correlated these atrophy patterns with cognitive changes and CSF biomarkers cross-sectionally and longitudinally, which may help us better understand the underlying pathology of AD.